Insights

Why the Orthocell (ASX:OCC) share price is flying higher today

Orthocell reports promising results on nerve repair for patients following serious injury.
The post Why the Orthocell (ASX:OCC) share price is flying higher today appeared first on The Motley Fool Australia. –

The Orthocell Ltd (ASX: OCC) share price is gaining in morning trade, up 3.3%.

Below we take a look at the regenerative medicine company’s latest clinical update.

What did Orthocell report?

Orthocell’s share price is gaining after the company updated the market on the interim results of its clinical CelGro nerve regeneration trial 12 months post treatment.

The results of the trial showed evidence of nerve repair using CelGro following serious injuries, including spinal injuries, as well as for the restoration of arm and hand function. Hence, Orthocell said its trial shows the potential for “breakthrough nerve treatment to return function to paralysed upper limbs”.

The data indicated that 75.8% (25 out of 33) of the nerve repairs in the trial resulted in functional recovery of muscles 12 months after treatment. 76.5% (13 out of 17) of nerve repairs in the quadriplegic patients also resulted in functional recovery 12 months after treatment.

Commenting on the results, Orthocell’s managing director, Paul Anderson said:

Consistently returning function to paralysed upper limbs is the primary goal in this study. I am delighted by the 12-month follow up results, our most complete data set to date, demonstrating higher quality outcomes, improved predictability, and consistency of return of muscle function following CelGro nerve regeneration treatment.

Clinical trial lead, Dr Alex O’Beirne added: “The quadriplegic patient results are particularly promising, with improved results at 12 months post treatment compared to the literature. CelGro is increasing the success rate and efficiency of nerve transfer surgery.”

Looking ahead

Orthocell said it expects the final 24 month results of the CelGro study in the second quarter of the 2022 calendar year. Its currently preparing to meet with the United States Food and Drug Administration (FDA) to get CelGro approved for use in the US.

According to the release, the global addressable market for CelGro is worth more than US$7.5 billion (AU$10 billion) per year, spanning some 3 million potential nerve repair procedures.

Orthocell share price snapshot

Over the past 12 months, Orthocell’s shares have gained 74%, far outpacing the 24% gains posted by the All Ordinaries Index (ASX: XAO).

Year-to-date the Orthocell share price has continued to outperform, up 28% so far in 2021.

The post Why the Orthocell (ASX:OCC) share price is flying higher today appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

Here’s why the Orthocell (ASX:OCC) share price is on the move today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!